Cis-diamminedichloride platinum II (DDP) in the treatment of penile carcinoma

Sklaroff, Robert B.; Yagoda, Alan

doi:10.1002/1097-0142(197911)44:5<1563::aid-cncr2820440503>3.0.co;2-s

Cited by 46 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Single-agent response rate to cisplatin is 23% ( Sklaroff and Yagoda, 1979 ; Ahmed et al , 1984 ; Gagliano et al , 1989 ), which is not dissimilar to the overall response rate of 30.8% reported for irinotecan and cisplatin in the EORTC single-arm phase II trial ( Theodore et al , 2008 ). The combination of cisplatin and 5-flurouracil (PF) has been used to treat advanced squamous carcinoma of the penis since 1990 and is widely regarded as the standard of care in this setting.…”

mentioning

confidence: 57%

Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001)

et al. 2013

View full text Add to dashboard Cite

Background:Penis cancer is rare and clinical trial evidence on which to base treatment decisions is limited. Case reports suggest that the combination of docetaxel, cisplatin and 5-flurouracil (TPF) is highly active in this disease.Methods:Twenty-nine patients with locally advanced or metastatic squamous carcinoma of the penis were recruited into a single-arm phase II trial from nine UK centres. Up to three cycles of chemotherapy were received (docetaxel 75 mg m−2 day 1, cisplatin 60 mg m−2 day 1, 5-flurouracil 750 mg m−2 per day days 1–5, repeated every 3 weeks). Primary outcome was objective response (assessed by RECIST). Fourteen or more responses in 26 evaluable patients were required to confirm a response rate of 60% or higher (Fleming-A'Hern design), warranting further evaluation. Secondary endpoints included toxicity and survival.Results:10/26 evaluable patients (38.5%, 95% CI: 20.2–59.4) achieved an objective response. Two patients with locally advanced disease achieved radiological complete remission. 65.5% of patients experienced at least one grade 3/4 adverse event.Conclusion:Docetaxel, cisplatin and 5FU did not reach the pre-determined threshold for further research and caused significant toxicity. Our results do not support the routine use of TPF. The observed complete responses support further investigation of combination chemotherapy in the neoadjuvant setting.

show abstract

mentioning

confidence: 57%

Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001)

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Three of the eight patients with adjuvant treatment showed no evidence of disease after a mean (range) of 54 (41-76) months, while four in this group died from disease progression after a mean of 11 (5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20) months, and one died from treatmentrelated toxicity. All five patients with metastatic disease died from disease progression after three had shown temporary signs of regression.…”

Section: Resultsmentioning

confidence: 99%

“…Unfortunately, for metastatic penile SCC there are no effective chemotherapy regimens and the existing combined regimens are often limited by their toxicity profile. We used a combined chemotherapy regimen of cisplatin, methotrexate and bleomycin (CMB), all of which have been shown to be active as single agents in penile carcinoma [6–9]. Although cisplatinum‐based treatment combinations show good results, there are no studies with large numbers of patients.…”

Section: Introductionmentioning

confidence: 99%

Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma

et al. 2006

View full text Add to dashboard Cite

OBJECTIVE To retrospectively evaluate the efficacy and toxicity of chemotherapy with cisplatinum, methotrexate and bleomycin (CMB) in the adjuvant and palliative setting, and its effect on survival in patients with locally advanced or metastatic penile carcinoma, which carries a very poor prognosis. PATIENTS AND METHODS Thirteen patients (mean age 54 years) with radically resected local and nodal disease (eight), metastatic disease (two) or metastatic recurrence (three) had chemotherapy with CMB between February 1996 and July 2003. In all, 45 treatment courses were given, with a mean (range) of 3.5 (2–6) courses per patient. RESULTS Three of the eight patients with adjuvant treatment showed no evidence of disease after a mean (range) of 54 (41–76) months, while four in this group died from disease progression after a mean of 11 (5–20) months, and one died from treatment‐related toxicity. All five patients with metastatic disease died from disease progression after three had shown temporary signs of regression. CONCLUSIONS Chemotherapy with CMB had little effect on metastatic penile cancer and responses were transient. However, patients with minimal disease after radical local and lymphatic resection seemed to benefit from adjuvant therapy, but the toxicity was high and carried a risk of death.

show abstract

“…A response rate (RR) of 23% to cisplatin monotherapy has been reported, 6–8 which is comparable to the overall response rate (ORR) of 30.8% reported for irinotecan and cisplatin in the single-arm phase II EORTC trial. 9 Three single-institution case series have reported a pooled RR of 63% with cisplatin and 5-flurouracil (PF) combination in 19 patients (three complete remissions and nine partial remissions).…”

Section: Discussionmentioning

confidence: 68%

Successful downstaging of locally recurrent penile squamous cell carcinoma with neoadjuvant nanosomal docetaxel lipid suspension (NDLS) based regimen followed by curative surgery

2017

View full text Add to dashboard Cite

Penile squamous cell carcinoma (pSCC) is a relatively rare disease in Western world but is a significant health problem in developing countries like India. We report here a case of successful multimodality management of recurrent pSCC with pelvic lymphadenopathy in a 56-year-old male patient with poorly controlled diabetes. The patient presented with ulceroproliferative growth over the residual penile stump clinically involving root of penis and with right pelvic lymphadenopathy. The patient had a history of partial penectomy done elsewhere 20 months ago. In view of the comorbidities, locally recurrent disease and presence of right Iliac lymphadenopathy, the patient was treated with nanosomal docetaxel lipid suspension (NDLS), cisplatin and 5-fluorouracil (TPF regimen) in the neoadjuvant setting followed by staged surgical resection. This is the first case report showing successful treatment of recurrent pSCC with NDLS-based TPF regimen in the neoadjuvant setting followed by staged surgery in a patient with poorly controlled diabetes.

show abstract

Cis-diamminedichloride platinum II (DDP) in the treatment of penile carcinoma

Cited by 46 publications

References 6 publications

Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001)

Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001)

Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma

Successful downstaging of locally recurrent penile squamous cell carcinoma with neoadjuvant nanosomal docetaxel lipid suspension (NDLS) based regimen followed by curative surgery

Contact Info

Product

Resources

About